Floatz logo

Allogeneic Donor Derived Lmp Specific Cytotoxic T-Lymphocyte

Hodgkins Lymphoma

New York Medical CollegeCell therapyPhase 2Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
95/ 100

Competitive context

141 Active assets in the Hodgkins Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB

View all 50 →

Same molecule, other indications

Allogeneic Donor Derived Lmp Specific Cytotoxic T-Lymphocyte is also rated in:

lymphoproliferative syndromeDormant
C
Indicative ·
32 / 100
View asset →
nasopharyngeal carcinomaDormant
C
Indicative ·
32 / 100
View asset →
leiomyosarcomaDormant
C
Indicative ·
32 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →